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ABSTRACT
Access to positron emission tomography (PET), and more recently PET combined with
computed tomography (PET/CT), is increasing in veterinary medicine. This molecular
imaging technology allows clinicians to map biological functions within patients based
on the distribution and selective uptake of specialized positron-emitting
radiopharmaceuticals. Although most clinical studies utilize 2-deoxy-2-[18F]fluoro-Dglucose ( 18FDG), a versatile but relatively nonspecific tracer that interrogates the energy
metabolism of tissues, there is a growing need to establish reference values for
alternative or adjunct tracers in veterinary species. Among these is 3’-deoxy-3’[18F]fluorothymidine (18FLT), a thymidine analog that selectively accumulates in
proliferating tissues. In the present work,

18

FLT distribution in clinically healthy adult

dogs and young adult cats was imaged using a state-of-the-art PET/CT scanner to
define normal uptake levels within numerous tissues, including major parenchymal
organs, bone marrow, and other sites of increased radiopharmaceutical uptake. The
marrow signal was subsequently segmented into separate skeletal regions, and used to
quantitatively define the adult marrow distribution pattern in the dog. Marrow activity is
concentrated in the vertebral column (particularly within the thoracic and lumbar
regions), sternum, ribs, and proximal aspects of the appendicular skeleton in the adult
dog. Feline marrow distribution is similar; however, considerable uptake within more
distal appendicular structures suggests that age-related marrow conversion is ongoing
in 3-year-old cats. Outside the marrow compartment, physiologic uptake was observed
within the urinary and biliary systems, intestinal tract, and variably within lymphoid
structures. Prominent uptake within the hepatic parenchyma was also observed in cats,
iii

but not dogs, at the times imaged in this study. The details of normal canine and feline
18

FLT biodistribution included in this dissertation may be used to inform lesion

interpretation in dogs and cats with suspected disease. Likewise, quantitative details of
adult marrow distribution in dogs may be used by clinicians to guide the selection of
marrow sampling sites or inform tissue-sparing efforts during radiotherapeutic planning
in canine patients.
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INTRODUCTION
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Basic Historical and Technical Aspects of Positron Emission Tomography (PET)
Functional imaging utilizing PET technology has played an increasingly important role in
the management of human diseases in the past several decades [1-3]. Although the
technology has existed since the 1960s [4], it was the late 1970s and 1980s when
clinical interest began to develop around its use. Early reports predominately describe
use in brain and cardiac disorders [4, 5]. At present, however, a PubMed search for
“positron emission tomography” will yield over 70,000 results covering a broad range of
applications ranging from psychiatry to oncology. The breadth of possible applications
relates to the core functional element of PET, the radiopharmaceutic al.
A PET radiopharmaceutical represents the coupling of two distinct functional
components: a molecular vehicle that drives distribution within the patient and a
positron-emitting radionuclide that allows that distribution to be detected, imaged, and
quantified [6, 7]. The pharmaceutical vehicle may interact with a patient’s body through
any of a variety of biologic processes in order to drive distribution of the tracer.
Examples include cell surface interactions such as antigen–antibody coupling or
receptor binding, acting as substrates for enzymes or transporters, or participating
directly in metabolic processes [6]. Ultimately, selection of the pharmaceutical vehicle
depends on the physiologic process that is being investigated. Although the
radionuclide serves predominately as a label for detection, its selection must balance
availability, practicality, and any potential impacts on the functional characteristics of the
radiopharmaceutical. There are several positron-emitting radionuclides from which to
choose (15O, 13N, 11C,

18

F, 68Ga, and a few others); however,

18

F is used most
2

commonly in the clinical setting due to its ability to be substituted into a number of
biologically relevant molecules, manageable effects on biochemical characteristics,
favorable imaging characteristics, and convenient half-life of 109.8 minutes [6, 7].
Detection and localization of tracer distribution is possible due to the unique physical
properties of positron emission. When a positron-emitting radionuclide decays by
transmutation of a proton to a neutron with the corresponding release of an electron
neutrino, and more importantly, a positron (essentially a “positive electron”), that
positron travels only a short distance before effectively running out of energy and
annihilating with an electron from the surrounding tissue [7-9]. The distance traveled by
the positron depends on the energy with which it is emitted, a characteristic of the
particular isotope. For

18

F (with an E max of 633 keV), that range is around 0.6 mm on

average [7]. The annihilation event results in the conversion of the masses of the two
particles to a pair of characteristic 511 keV gamma rays, released almost exactly 180º
apart. Ideally, these photons will strike opposing detectors of the PET camera in
coincidence, allowing recovery of the location of the annihilation event along a line of
response (LOR) connecting the detectors – a so-called “true” coincidence event. Each
paired event is stored within the computer and used to reconstruct the distribution of the
radioactivity using a reconstruction algorithm, thereby indirectly mapping the functional
process being interrogated [2, 7-9].
Historically, spatial resolution has been a limitation of PET with that of early scanners
exceeding 15 mm [2]. In part, this is due to intrinsic limitations imposed by the physics
of positron emission. Since LORs indicate the location of the annihilation event rather
3

than the actual position of the tracer, positron range inherently degrades spatial
resolution. Moreover, if the kinetic energy carried by the positron is not entirely
dissipated prior to annihilation, the resultant photons will be released at an angle less
than 180º to conserve that momentum and the LOR assigned by the scanner will
misrepresent their origin [7, 8]. While these effects impose a lower limit on achievable
spatial resolution, there are a variety of other factors that can produce more substantial
influences on image quality. True coincidences represent only a fraction of the total
counts detected, and not all annihilation photons will even reach the detectors due to
attenuation. Scatter, whereby photons interact with the tissue and are redirected prior to
reaching the detectors (albeit at some energy less than 511 keV), and random
coincidences, whereby 2 photons from unrelated annihilation events happen to strike
apposing detectors within the coincidence time window, both contribute to background
noise and degrade image quality [7]. Fortunately, improvements in detector design and
materials (resulting in faster scintillation, reduced dead time, and improved energy
resolution), electronics, and reconstruction algorithms have greatly improved image
quality in modern clinical scanners with typical resolutions now in the 4-5 mm range [2,
7, 10].
Fusion of PET data with computed tomography (CT) has further enhanced clinical utility.
While functional PET images generally offer little morphological information, CT can
provide the high-resolution anatomical detail necessary to reliably localize variations in
uptake [11, 12]. Beyond visual comparison of the two modalities by the reader, spatial
co-registration of both datasets has been shown to further improve lesion localization
accuracy [13]. Fusion was initially performed using software-based methods to align
4

scans produced by separate machines; however, time progression and movement
between scans (particularly that of internal organs which cannot be eliminated) often
complicated the process and success was limited beyond the brain [11]. More recently,
combined PET/CT scanners, introduced in the late 1990s and early 2000s, have largely
solved the alignment problem and expanded the utility of PET-CT fusion [3]. Inclusion of
both modalities within a single housing has allowed the scans to be performed in
immediate succession with no alterations to patient position. As such, this has produced
more consistent co-registration and increased efficiency, as well as a convenient
opportunity for improved attenuation correction [11].
The degree to which tissues attenuate the signal from annihilation photons must be
taken into account and corrections must be performed during image reconstruction to
ensure the quantitative integrity of uptake data. Without attenuation correction, uptake is
typically artifactually increased in the skin and lungs and non-uniform in other organs
such as the liver and spleen. In order to calculate correction factors, stand-alone PET
scanners require additional transmission scans with an external source of high energy
photons (e.g. 68Ge rods). These scans extend overall imaging time and introduce
additional noise into the data since the process relies on photon counting statistics [7].
Conversely, modern PET/CT scanners are able to make use of co-registered CT data to
obtain the necessary correction factors. In this context, the patient’s CT scan, which can
be performed in a fraction of the time needed to perform a separate PET-based
transmission scan, provides what is essentially a map of attenuation coefficients at the
mean CT x-ray energy (70-80 keV) [3, 7, 9, 12]. Although the data must be scaled to
match the PET energy of 511 keV, CT-based correction is essentially noiseless and can
5

reduce scan times by more than 40% [3, 11, 12]. Accordingly, PET/CT continues to gain
popularity and has become increasingly available at referral imaging facilities [2, 3, 14,
15].
Current Status and Limitations of 2-Deoxy-2-[ 18F]Fluoro-D-Glucose ( 18FDG)
At present,

18

FDG is by far the most commonly used PET tracer in the clinical setting

[6]. This 18F-labelled tracer is an analog of glucose that participates in the hexokinase
reaction of glycolysis. The product of this reaction,

18

FDG-6-PO 4, is denied further

metabolic progression due to the absence of a hydroxyl group at C-2 and becomes
trapped within cells [16, 17]. The absence of a hydroxyl group at C-2 also prevents
resorption in the renal tubule, increasing excretion of extracellular
background activity. As a result, imaging

18

18

FDG and reducing

FDG distribution provides a map of tissue

glycolytic activity with favorable signal-to-noise ratios for lesion detection in most tissues
[17]. Human physiologic uptake normally occurs in metabolically active tissues
(particularly the brain, but also skeletal muscles and myocardium under certain
conditions, as well as variable uptake in lymphoid and gastrointestinal structures). Since
18

FDG is eliminated via the urine, intense uptake in the renal pelves, ureters, and

urinary bladder is also a normal and prominent component of

18

FDG distribution in

humans [18-23]. Similar distribution is observed in common veterinary species [24-30].
Researchers have used

18

FDG since the late 1970s [31] and it remains the first-line

PET tracer for most clinical applications, including oncology, cardiology, and neurology
[15, 32]. Since most pathologic conditions are accompanied by alterations in glucose
management, 18FDG is especially versatile. Unfortunately, the nonspecific nature of
6

altered glucose metabolism can also represent a major drawback in certain situations
[6]. Although

18

FDG-PET is highly sensitive for detecting both primary and metastatic

tumors due to their characteristic increased energy consumption, false-positive uptake
is often also present in areas of infection or inflammation [23, 33, 34]. The utility of
18

FDG in measuring response to certain treatments, particularly those that often incite

an inflammatory response, can be complicated [35, 36], and not all tumors are 18FDG
avid [37, 38]. Moreover, physiologic uptake in metabolically active tissues can influence
18

FDG’s ability to discriminate lesions in these areas [18-20, 22, 23, 39]. While 18FDG

will likely remain the workhorse of clinical PET for the foreseeable future, there is a
need for validating alternative and adjunct imaging options for applications where a
traditional 18FDG-PET scan is inadequate or inappropriate [40]. Direct measurement of
proliferation frequently offers greater specificity than indirect measurement via energy
metabolism. Consequently, radiopharmaceuticals that specifically target the pathways
of DNA synthesis offer a useful alternative to characterize proliferative disorders [41].
3’-deoxy-3’-[ 18F]Fluorothymidine (18FLT) as a Proliferation Tracer
18

FLT, a close variant of the antiviral compound 3'-azido-3'-deoxythymidine (AZT), is the

most prominent proliferation marker currently used in PET imaging [6, 42]. Both
compounds are analogs of thymidine, the only nucleoside used in the production of
DNA that is not also incorporated into RNA [43-45]. Structurally,

18

FLT differs from

thymidine only by the presence of the 18F-label rather than a hydroxyl group at the 3’
position [46].

7

18

FLT uptake is facilitated by the pyrimidine salvage pathway, the mechanism by which

thymidine and its analogs are transported into cells and phosphorylated as an initial
step toward DNA synthesis [41]. Entrance into the cell is accomplished by both
facilitated transport and passive diffusion [42], while phosphorylation occurs via
thymidine kinase 1 (TK1) [43]. Phosphorylated 18FLT is trapped intracellularly, but
lacking the necessary 3’-hydroxyl, never significantly incorporated into DNA [47].
Consequently, it is phosphorylation by TK1 that forms the basis of

18

FLT accumulation

rather than the entirety of DNA synthesis. This is very similar to the underlying
mechanism of

18

FDG, wherein phosphorylation by hexokinase rather than progression

through the entirety of glucose metabolism is responsible for tracer retention [48].
Despite not being incorporated into DNA, there are several aspects of

18

FLT metabolism

that make it a suitable marker of proliferation. First and foremost, TK1 function is tightly
regulated – activity is increased in proliferating and malignant cells but essentially
absent in quiescent cells [49, 50]. Expression increases 10-fold during the synthetic
phase of the cell cycle, but rapidly declines thereafter [49, 51]. Secondly, putative
deoxynucleotidase-mediated dephosphorylation of

18

FLT-monophosphate, the product

of TK1, occurs slowly. Since the cell membrane is impermeable to phosphorylated
18

FLT, sluggish dephosphorylation limits efflux of the tracer and allows a stable retention

window for imaging [52]. Finally, unlike thymidine, 18FLT is not degraded by thymidine
phosphorylase (which would produce labeled metabolites) [52, 53], nor is it a substrate
for thymidine kinase 2 (the isozyme involved in mitochondrial, rather than nuclear, DNA
replication and repair) [54]. These factors simplify image analysis and link

18

FLT

exclusively to nuclear DNA synthesis [41].
8

Oncologic imaging represents an obvious application for a tracer that measures cellular
proliferation.

18

FLT uptake has been shown to correlate strongly with traditional

measures of proliferation, including Ki-67 immunostaining, for a variety of human
cancers [41, 47, 55]. Unfortunately, however, there are a number of factors that can
influence 18FLT uptake. It is important to consider the cell population that is being
interrogated when evaluating suitability. Since it is the salvage pathway that governs
retention of the tracer, factors that influence the utilization of this pathway, such as the
existing cellular thymidine concentration or predilection toward the de novo pathway, will
impact imaging performance [56, 57]. Likewise, recent administration of certain
chemotherapeutic agents that cause upregulation of the salvage pathway, like 5fluorouracil or methotrexate, may confound interpretation [58]. 18FLT-based imaging
often displays lower uptake levels and/or sensitivity when compared to

18

FDG for

detecting most cancers [47, 59-66]; however, greater specificity in many applications,
particularly when inflammation or lymph node involvement may be implicated, supports
that there is a role for

18

FLT in cancer imaging [62-67]. While it is unlikely that

18

FLT will

replace 18FDG for most initial tumor detection or staging efforts, a number of recent
studies have demonstrated promising results for the use of

18

FLT in evaluating

treatment response or predicting relapse [68-73].
Physiologic Distribution and Metabolism of

18

FLT

Human studies have primarily demonstrated physiologic

18

FLT uptake in the bone

marrow, liver, kidneys, and urinary bladder. Bone marrow is a known site of abundant
proliferation related to blood cell production. The other organs are primarily involved in
9

metabolism or excretion of the tracer. Unlike

18

FDG, little to no uptake is seen in the

brain, myocardium, or skeletal muscle [47, 74]. Preclinical work in the canine exhibited
similar qualitative biodistribution to the human, although hepatic parenchymal uptake
was reduced and uptake was also noted in the mandibular lymph nodes and muzzle
[43]. Lymph node aspirates were not collected, but the observed lymphoid uptake may
have been due to reactive B-lymphocyte proliferation within germinal centers [75].
Metabolism within the liver occurs via glucuronidation, the process by which glucuronic
acid is transferred to chemical compounds to form metabolites that are more hydrophilic
and readily excreted [76]. Glucuronidation is facilitated by a group of conjugative
enzymes known as UDP-glucuronosyltransferases (UGTs) which originally evolved to
detoxify various chemicals found in dietary plants but are now important contributors to
drug metabolism [77]. The specific isozyme responsible for AZT glucuronidation in
humans is UGT2B7 [78]; therefore, it is likely that this isozyme also facilitates
metabolism. In the human, this process is an important contributor to
with approximately 25% of the plasma activity present as

18

18

FLT

18

FLT kinetics,

FLT-glucuronide at 60

minutes post-injection [76]. Conversely, analyses of canine blood and urine suggest that
the glucuronide pathway contributes very little to 18FLT elimination in the dog and that
the vast majority of

18

FLT is excreted unchanged [43, 79, 80]. These findings likely

explain the disparity observed in hepatic uptake between the two species, and are
consistent with the in vitro metabolism of AZT by cultured hepatocytes. This suggests
glucuronidation is far more active in the livers of humans than of dogs [81].

10

Unfortunately, there appear to be no data available concerning the metabolic fate of
18

FLT or AZT in cats; however, multiple UGTs, including UGT2B7, are known to be

minimally expressed or absent in the feline liver [82]. As obligate carnivores, cats likely
had little need for these enzymes during their evolution, but their absence now impacts
the metabolism of several pharmaceutical agents. Most notably, the prolonged
clearance and remarkable sensitivity to the adverse effects of certain nonsteroidal antiinflammatory drugs in cats is attributed to diminished glucuronidation capacity [77, 83].
It is not clear whether alternative metabolic pathways exist in cats which may impact
metabolism of

18

FLT.

Bone Marrow Assessment Using 18FLT
As a prominent feature of physiologic distribution,

18

FLT uptake in bone marrow has

been comprehensively defined in humans [47, 74, 84]. Kinetic evaluation shows rapid
early accumulation and persistent high retention of

18

FLT in proliferating marrow. In part,

this is because the salvage pathway is particularly robust in the marrow related to the
recovery of DNA lost during red blood cell enucleation [85]. As a non-invasive, wholebody means to quantitatively evaluate hematopoietic marrow,

18

FLT has garnered

attention in human medicine not only for its ability to delineate normal active marrow
sites to maximize tissue sparing during external beam radiation planning [84, 86, 87],
but also for characterizing hematopoietic disorders [88-90]. Several studies have
likewise utilized 18FLT to illustrate the exquisite sensitivity of cycling bone marrow to
radiation insult [91-94]. Irradiation of the marrow with as little as 2 Gy has been shown
to visibly reduce uptake of the tracer, presumably due to cell cycle arrest, while a
11

fractionated dose of 10 Gy appears to have been sufficient to cause hematopoietic cell
death within the radiation field [92].
Similar applications are logical and worthwhile in veterinary species. In particular, with
growing veterinary access to advanced tissue-sparing radiotherapy techniques [95],
comprehensive, species-specific descriptions of active marrow distribution will be
increasingly relevant to veterinary clinicians concerned about inducing hematologic
toxicity.
18

FLT-PET in Veterinary Medicine

Access to PET and PET/CT remains relatively limited in veterinary medicine, although
usage in academic settings is gaining traction. In part, this is due to growing recognition
that the use of advanced techniques in animals can improve not only animal health, but
also that of humans through research collaborations between physicians and
veterinarians [67].
Similar to human medicine, most veterinary PET imaging is performed with
however, a number of investigators have begun using

18

FDG [15];

18

FLT in recent years to image a

variety of canine cancers including bronchoalveolar carcinoma [96], lymphoma [70],
fibrosarcoma [97], and various sinonasal tumors [80, 98-102]. Many of these studies
have focused on the utility of

18

FLT for measuring or predicting response to therapy with

favorable results [70, 96, 97, 100, 102].
Despite growing veterinary interest, quantitative details of normal

18

FLT biodistribution in

veterinary species remain limited in the literature [1]. Comprehensive knowledge of
12

normal distribution and relative uptake levels within a given species is an integral
component of image interpretation as readers must be able to reliably discriminate
abnormal from normal uptake within tissues [103]. Although the dog was used as a
model during early in vivo evaluations of

18

FLT [43, 79], these descriptions offer few

quantitative details for evaluation, not all areas of uptake visible in the included images
are discussed, and image quality is considerably lower than what is possible today with
modern PET/CT.
Quantifying Uptake in PET Images
Each voxel within a PET image represents the activity concentration (Bq/ml) within that
volume. As a result, PET images are inherently quantitative [104]. Although clinical
interpretation is often based principally on visual assessment [1], quantitative analysis
can augment this process, and when scans are acquired and analyzed under
standardized conditions permit more objective comparisons to be made between
studies [104].
In basic terms, there are generally two approaches for quantifying uptake in PET
studies – kinetic analysis and static analysis. Since kinetic approaches require dynamic
imaging to be performed, which limits the field of study to a single bed position per scan,
most clinical PET studies rely on the calculation of standardized uptake values (SUVs)
from static images [104]. SUVs represent a “semi-quantitative” approach to analysis
which normalizes activity within a region of interest (ROI) based on the dose injected
and the size of the patient [105]. SUVs are most commonly calculated based on body
weight (i.e. SUV = tissue concentration (Bq/ml) / (injected dose [Bq] / body weight [g]),
13

but lean body mass or body surface area may also be used. A value of 1.0 suggests
that there is no meaningful concentration of the tracer by a given tissue, while values
greater than 1.0 indicate that some mechanism of concentration is occurring [106]. SUV
calculations may be based on maximum, minimum, or average tissue concentrations,
but maximum values are most commonly used in lesion analysis [15].
Despite their popularity, SUVs have been criticized because they are subject to
variability from a number of sources, including several patient-, protocol-, and
equipment-related elements [107]. Among these elements are factors such as patient
body condition, competing transport effects (e.g. competition for glucose transporters
with elevated circulating glucose concentrations in the case of

18

FDG), dose

administered, length of uptake period, ROI size and designation parameters,
reconstruction method, and equipment capabilities [104, 107-109]. Nevertheless, kinetic
approaches suffer from many (though not all) of the same influences, and SUVs are
considered to be similarly discriminating diagnostically [105]. Regardless of method,
comparisons between institutions require careful consideration of all image acquisition
and analysis factors and should be approached cautiously. Although comparisons
between institutions should be approached cautiously, SUVs calculated with strict
adherence to data acquisition and analysis protocols can be a fairly reliable and
reproducible measure of tissue uptake [104]. Accordingly, most quantitative descriptions
of tracer biodistribution, at least within the veterinary literature, have utilized the SUV
[24-26, 110-112].

14
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PART 1
WHOLE-BODY BIODISTRIBUTION OF 3'-DEOXY-3'-[18F]FLUOROTHYMIDINE
(18FLT) IN HEALTHY ADULT CATS
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This part was previously published as a paper by Rowe JA, Morandi F, Wall JS, Akula
M, Kennel SJ, Osborne D, Martin EB, Galyon GD, Long MJ, Stuckey AC, and
Leblanc AK in Veterinary Radiology and Ultrasound:
Rowe JA, Morandi F, Wall JS, et al: Whole-body biodistribution of 3'-deoxy-3'[18F]fluorothymidine (18FLT) in healthy adult cats. Vet Radiol Ultrasound 54:299306, 2013.
My primary contributions to this paper include (1) developing the project and getting
IACUC approval in collaboration with mentor, (2) assistance with performance of the
scans, anesthesia, and transport (3) image and data analysis (4) creation of figures and
tables (5) most of the writing.
Abstract
Positron emission tomography/computed tomography (PET/CT) utilizing 3'-deoxy-3'[18F]fluorothymidine (18FLT), a proliferation tracer, has been found to be a useful tool for
characterizing neoplastic diseases and bone marrow function in humans. As PET and
PET/CT imaging become increasingly available in veterinary medicine, knowledge of
radiopharmaceutical biodistribution in veterinary species is needed for lesion
interpretation in the clinical setting. The purpose of this study is to describe the normal
biodistribution of

18

FLT in adult domestic cats. Imaging of six healthy adult castrated

male cats was performed using a commercially available PET/CT scanner consisting of
a 64-slice helical CT scanner with an integrated whole-body, high-resolution LSO PET
scanner. Cats were sedated and injected intravenously with 108.60 ± 2.09 (mean±SD)
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MBq of 18FLT (greater than 99% radiochemical purity by HPLC). Imaging was
performed in sternal recumbency under general anesthesia. Static images utilizing
multiple bed positions were acquired 80.83 ± 7.52 (mean±SD) minutes post-injection.
Regions of interest (ROIs) were manually drawn over major parenchymal organs and
selected areas of bone marrow and increased tracer uptake. Standardized Uptake
Values (SUVs) were calculated. Notable areas of uptake included hematopoietic bone
marrow, intestinal tract, and the urinary and hepatobiliary systems. No appreciable
uptake was observed within brain, lung, myocardium, spleen, or skeletal muscle.
Findings from this study can be used as baseline data for future studies of diseases in
cats.
Introduction
Positron emission tomography (PET) is a functional imaging modality widely used in
human medicine for the diagnosis and management of neoplastic and nonneoplastic
diseases [1]. More recently, the fusion of functional PET data (which is generally
characterized by relatively low spatial resolution) with high-resolution morphologic data
from computed tomography (CT) has resulted in a powerful diagnostic tool capable of
precise anatomic localization of radiopharmaceutical uptake [2]. With PET and PET/CT
becoming increasingly available to veterinary researchers and clinicians, knowledge of
the normal biodistribution of popular radiopharmaceuticals in veterinary species is
needed in order to reliably discriminate normal from abnormal uptake.
At present, 2-deoxy-2-[18F]fluoro-D-glucose (18FDG), a metabolic tracer which
interrogates the glucose metabolism of tissues, remains the most commonly used PET
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tracer in the clinical setting, regardless of species [3-5]. Although 18FDG will likely
remain the workhorse of clinical PET for the foreseeable future, the nonspecific nature
of increased glucose consumption as an indicator of disease can make it difficult in
some situations to discriminate malignancy from inflammation or to identify 18FDG avid
lesions within metabolically active normal tissues like the brain [6, 7].
Radiopharmaceuticals that specifically target the pathways of DNA synthesis offer a
useful alternative to aid in the characterization of proliferative disorders [8]. 3’-deoxy-3’[18F]fluorothymidine (18FLT) is the most prominent proliferation marker currently used in
PET imaging [3, 9]. As a thymidine analog, 18FLT participates directly in the salvage
pathway of DNA synthesis as a substrate for thymidine kinase 1 (TK1) [9, 10].
Phosphorylation by TK1 results in
basis of

18

FLT becoming trapped within cells and forms the

18

FLT-PET imaging. Although 18FLT is not significantly incorporated into DNA

due to the absence of a 3’-hydroxyl moiety, TK1 activity is tightly regulated throughout
the cell cycle and most reports have demonstrated correlation between

18

FLT uptake

and more traditional measures of proliferation, including Ki-67 scores [8, 10].
Numerous studies in humans have demonstrated the utility of

18

FLT in the diagnosis,

staging, measurement of therapeutic response, and prediction of outcome in a variety of
malignancies [8].

18

FLT-PET has also been used to characterize proliferative bone

marrow in relation to therapeutic planning [11, 12], response to insult [13-15], and
hematologic disease [16-18]. Underscoring the potential for translation of this tracer into
veterinary applications, early preclinical studies included normal and diseased dogs and
two reports within the veterinary literature document the successful use of

18

FLT in dogs
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to characterize neoplastic disease and assess therapeutic response [9, 19-21]. To date,
however, there have been no reports detailing

18

FLT uptake or use in cats. The purpose

of this study was to describe 18FLT uptake in normal adult cats to facilitate use of

18

FLT-

PET for future clinical applications in this species.
Methods
Six healthy adult cats were acquired from a dedicated research colony maintained
through the laboratory animal facilities at the University of Tennessee. All cats were
purpose-bred domestic short hair castrated males, 3 years of age, and weighed 5.59 ±
0.73 kg (mean ± SD; range 4.77 – 6.41 kg). Animals were housed in Institutional
Animal Care and Use Committee (IACUC)-approved facilities throughout the study and
all procedures were conducted in accordance with a University of Tennessee IACUCapproved protocol. Subjects were deemed healthy based on results of physical
examination, recent hematology and clinical chemistry testing, and routine clinical
history as university-housed research animals. In addition, no abnormalities were noted
in any animal upon evaluation of whole-body computed tomography (CT) during the
study.
18

FLT was synthesized through the radiopharmaceutical facilities at the University of

Tennessee Graduate School of Medicine using a flow-based microfluidic chemistry
system. The resultant microreactor product was purified by semi-prep high-performance
liquid chromatography (HPLC) resulting in >99% radiochemically pure

18

FLT for

injection. All doses were verified to be free of endotoxin prior to injection.
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All animals were fasted for a minimum of 12 hours prior to general anesthesia for
imaging. Following intravenous catheter placement, subjects were sedated with
acepromazine (0.025-0.05 mg/kg) and butorphanol (0.2-0.4 mg/kg) and injected
intravenously with 108.60 ± 2.09 MBq 18FLT (mean ± SD). Animals were subsequently
confined to a small cage for approximately 1 hour in order to allow distribution and
tissue uptake of the radiopharmaceutical. Animals were then transferred to the scanner
bed where general anesthesia was induced via intravenous bolus of propofol (titrated to
effect; ≤ 4 mg/kg), followed by endotracheal intubation and anesthetic maintenance with
inhaled isoflurane.
All cats were imaged in sternal recumbency using the same PET/CT scanner (Biograph
mCT, Siemens Medical Solutions USA, Inc., Knoxville, TN ). This scanner combines a
64-slice helical CT scanner with a high-resolution lutetium oxy-orthosilicate (LSO) PET
scanner. The scanner incorporates a 50 cm transverse (x-y axes) by 21.8 cm (z axis)
diagnostic field-of-view within the 78 cm patient bore. Whole-body, static PET/CT
images were acquired 80.83 ± 7.52 (mean±SD) minutes after

18

FLT injection.

Following an initial topogram to define the area of interest, a CT scan was performed for
attenuation correction as well as to aid in image analysis. Computed tomography scans
were performed at 120 kV and 150 mAs, using the scanner’s automated radiation dose
reduction protocol (Care Dose™, Siemens Medical Solutions USA, Inc., Knoxville, TN)
and using a 0.8 pitch and a 0.6 mm slice width. Computed tomography data were
reconstructed using 5 mm and 2.5 mm slice thicknesses. Immediately following CT
acquisition, a whole-body PET scan was performed with no alteration in subject
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positioning. Five to 7 bed positions were necessary to encompass the entire body of the
cats. Positron emission tomography data were acquired for 3 minutes per bed position
with an energy window setting of 435-650 keV. Positron emission tomography data
were reconstructed using the scanner’s specific iterative reconstruction algorithm
(TrueX algorithm, Siemens Medical Solutions USA, Inc., Knoxville, TN) with 3 iterations
and 12 subsets, resulting in a reconstructed pixel size of 4.07 mm x 4.07 mm. Data
were normalized and corrected for dead time, attenuation, scatter, and radioactive
decay.
Regions of interest (ROIs) were manually drawn by a veterinarian trained in ROI
placement and molecular image analysis over sites of clinical relevance and areas of
increased tracer uptake, including major parenchymal organs and selected areas of
bone marrow (Figure 1.1A-D) using dedicated analysis software (Inveon Research
Workplace v3.0, Siemens Medical Solutions USA, Inc., Knoxville, TN). Most ROIs were
drawn using transverse plane images; however, dorsal plane images were used for
liver, renal cortices, spleen, intestine, and myocardium. Renal cortical ROIs were
carefully drawn such that the renal pelvis was excluded as intense activity within the
renal collecting system is associated with urinary excretion of the tracer. Large,
homogeneous volumes of tissue (liver, lung, and epaxial muscle) were assessed via
placement of single, spherical volumetric ROIs in a representative area. Care was
taken to avoid inclusion of large airways within the lung. Standardized uptake values
(SUVs) based on the mean and maximum voxel intensity values within each ROI were
calculated utilizing a previously described standard formula [22]:
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Bq
within ROI
SUV= ml
total Bq injected
weight (g)
All calculations were decay-corrected to injection time. The resultant

18

FLT-SUVs were

categorized based on the following definitions: (1) low = maximum SUV less than 1; (2)
mild = maximum SUV greater than 1 but less than 2.5; (3) moderate = maximum SUV
greater than 2.5 but less than 5; (4) intense = maximum SUV 5 or greater.
Results
Mean and maximum SUVs for selected ROIs are summarized in Table 1.1. The mean
SUV was not assessed for intestinal uptake due to the irregular uptake patterns. Wholebody images illustrating biodistribution patterns are provided in Figure 1.2A and B.
The greatest regional uptake values occurred in the urinary and hepatobiliary systems.
Variable mild to moderate intestinal 18FLT uptake was observed and included numerous
focal areas of increased uptake, predominately within the small intestine. However,
occasional foci of increased uptake were observed within the large intestine. It was not
possible to identify a specific portion of the intestine to draw a repeatable ROI because
the uptake was variably diffuse to multifocal. Therefore quantitative evaluation of
intestinal uptake was limited to calculation of a maximum SUV, and this was assessed
using a single dorsal plane ROI encompassing the majority of the small intestine. It was
also not possible to determine whether the intestinal uptake was due to tracer
accumulation within the intestinal wall, lumen, or some combination thereof.
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Considerable tracer uptake within the bone marrow was observed, ranging from mild to
moderate intensity (Figure 1.3A and B). The highest tracer uptake within the marrow
compartment was primarily associated with the vertebral column, sternum, and proximal
appendicular skeleton. Uptake within the distal aspect of the femur was also observed
and was consistently among the highest intensity regions within the bone marrow. Focal
marrow uptake was also observed within the regions of the external occipital
protuberance, humeral condyles, and mandibular condyles in some animals. Although
vertebral marrow uptake was assessed within the vertebral bodies of C6, T5, L4, and
the sacrum; tracer activity was present throughout the vertebral column (excluding the
caudal vertebrae).
Tracer uptake within the brain, lung, myocardium, and skeletal muscle was low. Splenic
uptake was mild (maximum SUV of 1.18, mean SUV below 1).
Discussion
Physiologic uptake of

18

FLT in the cats of this study appeared to be greatest in the

hematopoietic bone marrow, intestine, and the hepatobiliary and urinary systems.
Observed uptake in these regions for normal cats should therefore be taken into
consideration for future clinical applications in cats with suspected disease. Minimal
uptake in the normal brain, lung, myocardium, skeletal muscle, and spleen should also
be taken into consideration for future clinical studies. These general patterns were
consistent with normal uptake in other species that have been previously described.
Intense activity within the urinary system was most likely due to elimination of the tracer
via the kidneys. Moderate uptake within the hepatic parenchyma and intense activity
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within the gallbladder was unexpected and may have been caused by hepatic
metabolism and biliary excretion of

18

FLT. The pattern of uptake in the bone marrow

was expected, given that hematopoietic bone marrow is a well-known site of rapid
cellular proliferation. The salvage pathway is particularly active in marrow due to the
reclamation of DNA resulting from abundant red blood cell enucleation [23]. As
expected in an adult animal, marrow activity in our cats was predominantly concentrated
within the axial and proximal appendicular skeleton [24]. Indeed, the highest marrow
SUV measurements in this study were observed within the proximal aspect of the
humerus (maximum SUV = 4.85), a common site for bone marrow sample collection in
veterinary species. Iliac uptake was also observed. However, measurements were
higher in the caudal aspect of the body of the ilium (immediately cranial to the
acetabulum) than in the wing of the ilium (maximum SUVs of 3.03 and 1.86,
respectively). Interestingly, the distal femoral epiphyses had among the highest marrow
uptake measurements in this study (maximum SUV = 3.80). This is in contrast to the
established distribution of

18

FLT in humans where adult appendicular marrow uptake is

limited to the ultraproximal extremity bones [16].
All cats in this study were 3 years of age, thus no assessment of age-related marrow
conversion could be determined. Distribution of hematopoietic marrow varies as a
function of age. Although active marrow is found throughout the skeleton of newborn
mammals, it is progressively replaced by yellow or fatty marrow as the animal matures
[24]. Previous studies in dogs and humans have used magnetic resonance imaging
(MRI) to describe bone marrow composition. This technique has been used to describe
lumbar vertebral, pelvic, and femoral marrow characteristics in the adult canine as well
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as age-related marrow conversion in the canine pelvis, femur, and stifle joint [25-27];
however, no such data are available in cats. A report using T1-weighted magnetic
resonance imaging has evaluated age-related marrow conversion in the human
mandible. Human mandibular bone marrow conversion progresses caudally with the
condyle representing the final remaining region of active hematopoietic marrow and it
too disappears in adolescence [28]. Three of six cats in this study had observable tracer
uptake within the mandible, each limited to a focal area within the condyle. This
suggests that marrow conversion may still be taking place in 3-year-old cats. It is
unknown what effects age-dependent conversions would have on the increased tracer
uptake observed within the distal femora and variable uptake noted within the distal
humeri. Future studies are needed in cats of varying ages, particularly older animals, in
order to define differences in marrow SUVs that may be attributable to patient age.
Intestinal 18FLT uptake was present in all 6 cats although uptake pattern was irregular
and was typified by focal areas of increased tracer accumulation throughout the
intestine. Despite CT fusion, it was not clear whether the uptake was related to the
intestinal wall, lumen, or a combination of both sites. The addition of both intravenous
and oral contrast media administration to the CT imaging protocol may have enabled
this discrimination. Intestinal mucosa is a rapidly proliferative tissue and this most likely
explains some component of the intestinal uptake of

18

FLT we observed in our cats.

This is further supported by uptake present throughout the intestine, with scans
performed on fasted animals ≤92 minutes from tracer injection.
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In addition to intense uptake within the gallbladder, moderate hepatic tracer uptake was
observed in all cats in this study (maximum SUV = 4.00). Previous reports concerning
the metabolic fate of

18

FLT and/or the related compound 3’-azido-3’-deoxythymidine

(AZT) have indicated that hepatic metabolism via glucuronidation occurs to a variable
extent depending upon species [29]. Glucuronidation is the process by which glucuronic
acid is transferred to chemical compounds resulting in metabolites that are more
hydrophilic and readily excreted [30]. Strong hepatic uptake has been described as
characteristic of human

18

FLT biodistribution while canine hepatic uptake has been

found to be considerably less by comparison [9]. This relationship is consistent with
kinetic studies in each species which demonstrate that, while circulating
mostly unchanged in the dog,

18

18

FLT remains

FLT-glucuronide represents approximately one-fourth of

the measured blood activity at 60 minutes in humans [19, 23]. Aside from
phosphorylation by TK1 in the salvage pathway, glucuronidation is the only documented
major metabolic consequence of

18

FLT [23].

Following this logic, hepatic uptake in the domestic cat would be expected to be very
low. As an obligate carnivore, cats lack certain UDP-glucuronosyltransferases (UGTs),
the group of hepatic enzymes responsible for facilitating glucuronidation, due to genetic
mutations found throughout felidae. While these enzymes are mainly discussed in the
context of synthetic drug metabolism, they likely evolved in large part to detoxify dietary
chemicals encountered in plant-based diets. Since cats consume a diet composed
primarily of animal matter, these evolutionary selective pressures could be altered,
allowing genes which control these enzymes to become dysfunctional [30]. Diminished
glucuronidation abilities are considered responsible for the prolonged clearance and
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remarkable sensitivity of cats to the adverse effects of certain non-steroidal antiinflammatory drugs [31]. Our finding of relatively high hepatic tracer uptake in the face
of the poor glucuronidation capacity characteristic of cats may indicate that alternative
metabolic pathways are responsible for hepatic uptake in this species. Further studies in
a larger number of cats are needed to define the nature of the hepatobiliary
uptake, and to characterize the metabolic fate of

18

18

FLT

FLT in this species. The presence

of possible circulating metabolites may impact image analysis for future clinical patients.
Measurements of regional tracer uptake in this study were expressed using SUV. This
is a semiquantitative measure derived from static images that normalizes activity within
a ROI for the specific radiopharmaceutical dose administered and the individual
patient’s body weight. This measure is commonly used clinically because it allows
multiple bed positions to be assessed simultaneously from a single PET scan performed
at a fixed time post-injection [22, 32-34]. Despite widespread usage, the SUV has been
scrutinized as it can be influenced by several patient, scanner, and protocol-related
factors. Some important sources of variability include patient body composition, lesion
size and location, equipment specifications, duration of uptake period, choice of
reconstruction algorithm, and ROI designation parameters [22, 35-37]. As a result, strict
standardization and protocol adherence is necessary to achieve repeatability and
caution must be exercised when comparing SUV data between institutions and species
[35, 38].
As veterinary clinicians and researchers continue to gain access to PET technology,
availability of baseline biodistribution data in veterinary species will be critical. To the
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authors’ knowledge, this is the first report of
describes the physiologic uptake pattern of

18

FLT imaging in the cat. This study

18

FLT in a small cohort of healthy young

cats and can be used as a baseline for future clinical application and interpretation of
18

FLT-based imaging in this species. 18FLT-PET and 18FLT-PET/CT have already been

used successfully in humans to diagnose, characterize, and manage a variety of
neoplasms and hematopoietic disorders [8, 10-18]. Moreover, veterinary reports
involving naturally occurring canine lymphoma, sarcoma, and bronchoalveolar
carcinoma have demonstrated the utility of

18

FLT in detecting neoplastic lesions,

evaluating therapeutic response, and recognizing disease recrudescence in dogs; the
latter case report highlighting

18

FLT’s usefulness as an adjunct to 18FDG in the

presumptive discrimination of inflammation from proliferative tumor [9, 20, 21]. Potential
applications and indications for this imaging modality in the cat should mirror those
described in other species with obvious relevance to the field of oncology and
assessment of bone marrow proliferation. Physiologic uptake within the liver, bone
marrow, urinary system, and variable uptake within the intestine may complicate
detection of lesions within these tissues due to background uptake levels. Further
studies are needed to describe 18FLT uptake patterns in healthy cats of varying ages,
determine how 18FLT metabolism occurs in cats, and describe

18

FLT-PET/CT

characteristics in cats with confirmed diseases.
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Table 1.1 Mean and maximum standardized uptake values of

18

FLT uptake measured

with positron emission tomography/computed tomography for selected regions in
healthy, young adult cats (n=6)

Region of
Interest
Urinary Bladder
Gallbladder
Renal Cortex
Proximal Humerus
Liver
Distal Femur
Intestine
L4 Vertebral Body
Body of Ilium
Sacrum
Sternum
T5 Vertebral Body
Proximal Femur
Wing of Ilium
C6 Vertebral Body
Spleen
Epaxial Muscle
Myocardium
Brain
Lung

SUVmean

SUVmax

mean (SD)

mean (SD)

157.55
9.62
4.33
3.70
3.75
2.79

(55.73)
(2.46)
(0.80)
(0.95)
(0.38)
(0.76)
―
2.50 (0.71)
2.73 (0.84)
2.33 (0.63)
2.27 (0.69)
1.98 (0.46)
1.78 (0.64)
1.72 (0.31)
1.57 (0.45)
0.93 (0.13)
0.91 (0.10)
0.79 (0.10)
0.25 (0.06)
0.25 (0.04)

220.38
11.29
6.14
4.85
4.00
3.80
3.52
3.17
3.03
2.94
2.44
2.24
2.01
1.86
1.75
1.18
0.96
0.84
0.47
0.28

(69.14)
(3.12)
(1.43)
(1.39)
(0.44)
(1.11)
(0.71)
(0.98)
(0.96)
(0.77)
(0.78)
(0.41)
(0.76)
(0.48)
(0.51)
(0.15)
(0.11)
(0.12)
(0.10)
(0.05)

SUV, standardized uptake value; SD, standard deviation.
SUV’s for all paired structure regions of interest were calculated by summing data for both left
and right sides. Measurements were made 80.83 ± 7.52 (mean±SD) minutes after injection. All
SUVs were decay corrected to injection time.

54

Figure 1.1 Fused positron emission tomography/computed tomography (PET/CT)
images depicting how regions of interest (ROIs) were drawn for cats. (A) ROIs outlining
the left (purple) and right (yellow) renal cortices were drawn to exclude the renal
pelvises (asterisks) on dorsal plane images. A portion of the spherical liver ROI is
outlined in red. (B) Large dorsal plane ROI outlining the small intestinal tract (green). (C)
Transverse plane images were used to outline the 4 th lumbar vertebral body (light blue).
(D) Transverse plane ROI outlining uptake within the distal femoral epiphysis (blue).
S = stomach, Sp = spleen, black arrow head = tracer uptake within gallbladder.
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Figure 1.2 Representative images illustrating 18FLT whole-body biodistribution patterns
observed in healthy young adult cats at 80.83 ± 7.52 (mean±SD) minutes post-injection.
Dorsal (A) and sagittal (B) plane positron emission tomography maximum intensity
projections are provided. Each dorsal plane image corresponds to the sagittal plane
image directly below. Image display settings are the same throughout the series.
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Figure 1.3 Oblique 3-dimensional fused positron emission tomography/computed
tomography images highlighting 18FLT uptake within feline hematopoietic bone marrow.
(A) Note strong uptake within the proximal aspects of the humeri, a common marrow
sampling site in the cat. Uptake is also visible within the cervical and thoracic vertebral
bodies and sternum (B) Note strong uptake within the caudal aspects of the bodies of
the ilia and the distal aspects of both femora. Uptake is also present within lumbar and
sacral vertebral bodies.

57

PART 2
WHOLE-BODY BIODISTRIBUTION OF 3'-DEOXY-3'-[18F]FLUOROTHYMIDINE
(18FLT) IN HEALTHY ADULT DOGS
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This part is yet to be submitted for publication by Rowe JA, Morandi F, Wall JS, Akula
M, Kennel SJ, Osborne D, Martin EB, Galyon GD, Long MJ, Stuckey AC, Reed RB, and
Leblanc AK.
My primary contributions to this paper include (1) developing the project and getting
IACUC approval in collaboration with mentor, (2) assistance with performance of the
scans, anesthesia, and transport (3) image and data analysis (4) creation of figures and
tables, (5) all of the writing.
Abstract
Positron emission tomography/computed tomography (PET/CT) utilizing 3’-deoxy-3’[18F]fluorthymidine ( 18FLT), a marker of cellular proliferation, is increasingly recognized
as a useful tool in the characterization of various cancers and bone marrow function.
Although use of this technology in veterinary medicine has been limited, access to and
interest in PET and PET/CT is increasing. Accordingly, detailed knowledge of the
biodistribution of relevant tracers in veterinary species is required to properly interpret
studies in the clinical setting. The purpose of this study is to describe the normal
biodistribution of

18

FLT in dogs. Six healthy, adult, mixed-breed dogs were imaged

utilizing a commercially available PET/CT scanner consisting of a 64-slice helical CT
scanner combined with an integrated whole-body, high-resolution LSO PET scanner.
Imaging was performed in sternal recumbency under general anesthesia 77.10 ± 12.83
minutes (mean±SD) after animals received an intravenous injection of 93.36 ± 41.75
MBq 18FLT (mean±SD). Standardized uptake values (SUVs) were calculated based on
manually drawn regions of interest (ROIs) placed over major parenchymal organs,
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selected areas of bone marrow, and areas of increased tracer accumulation. Uptake
was observed primarily within the urinary and biliary systems, bone marrow, and
intestinal tract. Moderate uptake was variably observed in lymphoid tissues. Tracer
retention in the brain, lung, myocardium, skeletal muscle, and spleen was generally low
to mild, although a focal area of increased splenic uptake was observed in one animal.
Introduction
Veterinary interest in advanced imaging modalities, including positron emission
tomography (PET) and combined positron emission tomography/computed tomography
(PET/CT), is growing as clinicians and researchers gain access to equipment and
clients increasingly demand access to care for their animals that is similar to that in
human medicine [1-4]. Most PET and PET/CT studies have utilized 2-deoxy-2-[18F]fluoro-D-glucose (18FDG), a radiopharmaceutical analog of glucose whose uptake
reflects the energy utilization of tissues [5, 6]. The popularity of

18

FDG is due in large

part to its versatility, as many pathological and physiological conditions are
accompanied by alterations in glucose management [6]. Unfortunately, this also
underlies one of the major pitfalls of this tracer, particularly in the context of oncology. It
is not only tumors which accumulate the tracer, but also areas of inflammation and
various normal tissues which utilize glucose to meet their energy demands [7-11]. As a
result, alternative tracers must be investigated for applications where

18

FDG is either

inappropriate or inadequate.
3'-deoxy-3'-[18F]fluorothymidine (18FLT) is a radiopharmaceutical analog of thymidine
whose uptake and retention is more directly related to the cellular processes of
60

proliferation [12]. Similar to the way in which

18

FDG is trapped intracellularly following

phosphorylation early in the glycolytic pathway,

18

FLT is trapped after being

phosphorylated by thymidine kinase 1 (TK1) as part of the pyrimidine salvage pathway
of DNA synthesis [13-15]. Although it is not ultimately incorporated into DNA as it lacks
the necessary 3’ hydroxyl, TK1 activity is tied closely to the cell cycle and uptake of the
tracer has generally been shown to correlate favorably with traditional measures of DNA
synthesis [3, 14, 16, 17].
In recent years, 18FLT has become one of the most prominent of the so-called
“proliferation markers”, and its utility has been investigated for a broad range of human
cancers in the diagnosis, staging, and/or measurement of therapeutic response [14, 18].
It has also been used as a diagnostic tool to analyze various bone marrow dyscrasias
and to map normal proliferative marrow [19-24]. Although veterinary usage has been
more limited to date, clinical investigations have utilized

18

FLT-PET in the assessment

of a variety of canine cancers [2, 25-28]. Whole-body biodistribution of

18

FLT has been

described in the cat [29] and early descriptions of physiologic 18FLT distribution were
based on dogs; however, comprehensive descriptions of biodistribution are still needed
to aid image interpretation in this species [3, 12, 30]. The present study describes the
normal distribution of

18

FLT in a small cohort of healthy, adult dogs.

Methods
Six healthy, purpose-bred, mixed-breed dogs were obtained through the Laboratory
Animal Facilities at the University of Tennessee College of Veterinary Medicine. The
study sample included 2 males (one intact, one castrated) and 4 spayed females. Age
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ranged from 3 to 6 years (mean = 4.67 yrs) and weight ranged from 15.45 kg to 25.91
kg (mean = 19.09 kg). All animals were housed throughout the study in Institutional
Animal Care and Use Committee (IACUC)-approved housing facilities and all
procedures were conducted in compliance with a University of Tennessee IACUCapproved research protocol. Dogs were deemed to be healthy based on the results of
physical examination, recent hematology and clinical chemistry testing, as well as
routine history as university-maintained research animals. Additionally, no abnormalities
were observed in any animal upon evaluation of whole-body computed tomography
(CT) during the study.
The imaging protocol included general anesthesia for immobilization and positioning. All
animals were fasted for a minimum of 12 hours prior to placement of an intravenous
catheter in a peripheral vein and sedation with acepromazine (0.025-0.05 mg/kg) and
butorphanol (0.2-0.4 mg/kg). At the time of sedation, animals were intravenously
injected with 93.36 ± 41.75 MBq

18

FLT (mean±SD). The initial two study animals were

administered 146.34 ± 0.26 MBq (mean ± SD) while the dosage was reduced to 66.88 ±
9.98 MBq (mean±SD) in later animals with no appreciable alteration in imaging
characteristics. Following a 60-90 minute uptake period during which the animals were
confined to a small cage, general anesthesia was induced via intravenous bolus of
propofol (≤4 mg/kg) followed by maintenance with inhaled isoflurane.
18

FLT utilized in this study was produced on-site by the radiochemistry laboratory of the

Molecular Imaging and Translational Research Program at the University of Tennessee
Graduate School of Medicine via a flow-based microfluidic chemistry system. The
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reaction product was purified by semi-prep high-performance liquid chromatography
(HPLC) in order to yield >99% radiochemically pure 18FLT for injection.
PET/CT imaging was performed in ventral recumbency 77.10 ± 12.83 minutes
(mean±SD) after

18

FLT injection using a Biograph mCT scanner (Siemens Medical

Solutions USA, Inc., Knoxville, TN). This scanner combines a 64-slice helical CT
scanner with a high resolution LSO PET scanner within a single housing. The unit
incorporates a 78 cm patient bore with a 50 cm transverse (x,y) field-of-view; the z-axis
field-of-view covers 21.8 cm. CT and PET imaging were performed sequentially with no
alteration in subject positioning following an initial topogram defining the area of interest.
CT data were utilized for attenuation correction during PET reconstruction as well as to
aid image analysis. CT scans were performed at 120 kV and 150 mAs with Care
Dose™ using a 0.8 pitch and 0.6 mm acquisition slice width. CT data were later
reconstructed using 5 mm and 2.5 mm slice thicknesses for image analysis. PET
imaging required 9 to 11 bed positions in order to encompass the entire body of the
dogs and immediately followed completion of the CT scan. PET data were acquired for
3 minutes per bed position with an energy acceptance window of 435-650 keV. PET
reconstruction was performed using the TrueX algorithm (Siemens Medical Solutions
USA, Inc., Knoxville, TN) with 3 iterations and 12 subsets resulting in a reconstructed
pixel size of 4.07 mm x 4.07 mm. Data reconstruction included normalization and
corrections for dead time, attenuation, scatter, and radioactive decay.
Regions of interest (ROIs) were manually drawn by a veterinarian trained in molecular
imaging analysis over sites of observed tracer accumulation, major parenchymal
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organs, and selected regions of bone marrow (Figure 2.1) using a dedicated analysis
software package (Inveon Research Workplace v3.0, Siemens Medical Solutions USA,
Inc., Knoxville, TN). In total, 36 separate ROIs were designated for each animal. Most
regions were drawn 2-dimensionally using the imaging plane which most easily
facilitated creation of a representative ROI. Large, homogeneous organs (liver, lung,
urinary bladder, and epaxial muscle) were assessed via placement of individual
spherical volumetric ROIs within a representative area of each tissue; care was taken to
avoid large airways within the pulmonary parenchyma during placement. As urinary
excretion is known to be a predominate route of

18

FLT elimination, renal cortical ROIs

were drawn with care to exclude the renal pelvis from analysis. Mean and maximum
standardized uptake values (SUVs) were calculated based on measured body weight
using dedicated analysis software (Inveon Research Workplace v3.0, Siemens Medical
Solutions USA, Inc., Knoxville, TN) and are decay-corrected to the time of injection.
Tracer accumulation data was categorized based on the following definitions: (1) low =
maximum SUV less than 1; (2) mild = maximum SUV greater than 1 but less than 3; (3)
moderate = maximum SUV greater than 3 but less than 6; (4) intense = maximum SUV
of 6 or greater.
Results
Biodistribution of

18

FLT in the canine is summarized in Table 2.1 and is greatest in the

urinary and biliary systems, intestinal tract, and bone marrow. Tracer accumulation was
also variably observed within lymphoid tissues. Whole-body biodistribution images are
provided in Figure 2.2A and B.
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The 18FLT signal of greatest intensity was observed within the urinary bladder with
moderate activity also present within the renal cortices. Static

18

FLT signal within the

hepatic parenchyma was mild at the times of observation in this study; however, intense
radiopharmaceutical accumulation within the gallbladder was characteristic of all dogs
evaluated. Variable, multifocal to diffuse intestinal uptake was also observed, although it
was not possible to discriminate tracer uptake within the intestinal wall from
accumulation within the lumen.
Substantial tracer uptake within hematopoietic bone marrow was observed. All dogs in
this study demonstrated similar distribution of tracer activity within the marrow
compartment, with intense tracer uptake associated with the vertebral column, sternum,
and proximal appendicular skeleton. Appendicular

18

FLT signal was consistently low to

mild beyond the proximal aspect of the humerus and femur.
Lymphoid tissues also variably demonstrated radiopharmaceutical uptake in these
clinically healthy animals; while uptake was mild on average, measurements in
individual animals ranged from low to moderate. Although the superficial cervical and
popliteal lymph nodes were the only lymphoid sites for which ROIs were designated,
uptake was variably observed in other areas where lymphoid tissues are present (e.g.
palatine tonsil, retropharyngeal lymph nodes). Neither aspirates nor biopsies were
evaluated as a part of this study.
18

FLT uptake within the brain, lung, myocardium, skeletal muscle, and spleen was low

to mild with the exception of a single, focal area of intense uptake (SUV = 16.6) within
the spleen of one animal (Figure 2.3).
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Discussion
The present study further characterizes the physiologic distribution of

18

FLT in the

canine using PET/CT. Previous investigation in the normal dog utilizing PET without CT
fusion indicated retention of the tracer in the kidneys and urinary bladder as well as
selective uptake in tissues with a high proliferative rate like bone marrow. Tracer
accumulation was also visualized in mandibular lymph nodes, though SUV data was not
included [12]. Similar to previous findings, we observed intense physiologic uptake of
18

FLT within the urinary system and bone marrow. Accumulation within these tissues is

a hallmark of

18

FLT distribution across multiple species, the former due to elimination

via the urine, the latter due to the highly proliferative nature of hematopoiesis [12, 29,
30]. Additionally, we noted increased uptake within the biliary system, intestine, and
variable uptake within lymphoid tissues. Observed uptake within these regions in the
normal dog should therefore be considered when evaluating studies in dogs with
suspected disease. Likewise, tissues which display minimal uptake – the normal brain,
lung, myocardium, and skeletal muscle – should be kept in mind when considering
future clinical applications. The unexpected single focus of intense uptake within the
spleen of one animal is presumed to be caused by extramedullary hematopoiesis;
unfortunately, samples were not collected to allow confirmation. Splenic uptake was
otherwise mild in all animals suggesting that uptake in this organ is normally minimal.
Radiopharmaceutical elimination is a prominent component of the physiologic
distribution of

18

FLT in the domestic dog with the highest uptake observed in the urinary

and biliary systems. Considerable uptake within the renal cortices and urinary bladder is
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expected as 18FLT is cleared in large part via the urine, predominately (over 95%) as
unmetabolized FLT in the canine [12]. Previous in vitro studies of the related compound,
3’-azido-3’-fluorothymidine (AZT) utilizing cultured hepatocytes support that the canine
liver is responsible for very little metabolism of a similar substance [31]. This differs from
humans where robust hepatic glucuronidation occurs, resulting in the presence of
glucuronide-conjugates of the tracer in blood and urine [32, 33] and marked hepatic
uptake [12]. The present study confirms mild hepatic tracer retention in the dog as
compared to the human [12], although intense activity was present in the gallbladder. In
fact, measurements within the gallbladder were consistently among the highest in this
study, second only to the urinary bladder. While previous descriptions of the dog do not
mention tracer accumulation within the gallbladder, an early sagittal image illustrating
physiologic distribution displays a focal area of uptake in the appropriate location [12].
Further investigation evaluating bile and/or feces is needed to discern if the activity
within the gallbladder is present as the parent compound or a metabolite as well as to
what degree biliary excretion contributes to the distribution and elimination of the tracer.
Abundant uptake by the bone marrow is a key feature of physiologic

18

FLT distribution.

In addition to being a site of rapid proliferation, the salvage pathway utilized by

18

FLT is

particularly well-developed in hematopoietic marrow due to the need to recover DNA
liberated during red blood cell enucleation [33]. The pattern of marrow uptake observed
in these adult dogs closely mirrors that of adult humans with uptake concentrated in the
vertebrae, sternum, and ultraproximal appendicular skeleton [34]. Unlike our previous
observations in the young adult cat [29], discernable uptake was not present beyond the
proximal aspects of the humeri or femora in any of the dogs evaluated. Conversion of
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hematopoietic marrow to fat occurs with increasing age [35] and has been previously
studied in the canine pelvis, femur, and stifle joint using magnetic resonance imaging
(MRI). These studies suggest that conversion in the distal femur is a variable process,
but likely occurs between 1 and 3 years of age in the dog [36-38]. Our findings support
this assertion as conversion to an adult pattern appears to be complete in these 3-6
year old dogs.
Intestinal uptake is a frequently observed component of physiologic

18

FLT distribution in

several species [29, 39, 40], though it has not been previously quantified in the dog.
Moderate to intense intestinal uptake was present in all 6 dogs in this study. Distribution
was variably multifocal to diffuse so measurements were limited to maximum SUV
assessed over a large, dorsal plane ROI drawn over a representative portion of the
small intestine. It is likely that intestinal uptake is the result of proliferating intestinal
mucosal cells; however, given the intense uptake within the gallbladder, biliary excretion
may also contribute.
Variable lymphoid uptake in these clinically healthy animals may confound interpretation
of clinical studies, particularly when trying to distinguish reactive lymph nodes from
lymph node metastases. Uptake within superficial cervical and popliteal lymph nodes
was generally low to mild; however, moderate uptake was observed in two individuals,
neither of which displayed evidence of disease based on physical examination,
bloodwork, or anatomical imaging. Although other lymphoid sites were not measured in
this study, modest uptake was variably present based on visual inspection and uptake
within mandibular nodes has been previously reported as a component of normal
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canine biodistribution [12]. Although

18

FLT has been shown not to accumulate in

inflamed tissue since inflammatory cells are recruited from elsewhere [40, 41],
interpretation of lymph node uptake is more complicated. While several groups have
evaluated the specificity of

18

FLT for detecting lymph node metastases in a variety of

cancers, results have been mixed [42-47]. Troost et al, who reported very low specificity
for identifying lymph node metastases in 10 patients with head and neck cancer,
determined that uptake by non-metastatic reactive lymph nodes occurs in germinal
centers due to proliferating B-lymphocytes [46].
Regional uptake measurements in this study were expressed using the SUV, a semiquantitative measure which relates uptake within an ROI to the administered
radiopharmaceutical dose and patient weight. As SUVs are calculated from static
images, which allow the assessment of multiple bed positions within a single study, they
are a convenient and popular alternative in the clinical setting. Unfortunately, SUVs are
also subject to influence by a variety of patient, equipment, and protocol-related
elements beyond individual and species-specific physiologic factors. Among these are
body composition, scanner specifications, image reconstruction algorithm, length of
uptake period, and various aspects of the individual ROI such as size, method of
placement, and whether average or maximum activity values are utilized [48-52]. SUV
measurements of normal tissues in the dog are limited in the literature, but mean SUV
in the vertebral marrow has been reported to be approximately 4.7 [12, 30]. While this
measurement is somewhat lower than our measurements presented herein, it is difficult
to compare values due to variability between studies and it is unclear specifically where
previous measurements were assessed. While comparisons among species must be
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approached with caution, it is interesting to note that relative to our previous description
of feline 18FLT biodistribution [29], which used the same scanner and protocols, canine
marrow and biliary uptake is much higher, while uptake in the hepatic parenchyma,
renal cortices, and urinary bladder is lower. Further investigation is required to
determine the mechanisms responsible for these differences.
As PET and PET/CT continue to make inroads into veterinary medicine, detailed
descriptions of normal tracer distribution in veterinary species are needed to support
interpretation of studies in clinical patients. This study expands upon initial descriptions
of 18FLT distribution in the dog [12, 30] and provides reference data from healthy, adult
animals for comparison. Further studies are needed to define the implications of biliary
tracer accumulation and to validate 18FLT characteristics in canine patients with
confirmed disease.
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Table 2.1 Mean and maximum standardized uptake values of

18

FLT uptake measured

with positron emission tomography/computed tomography for selected regions in
healthy, adult dogs (n=6)

Region of Interest
Urinary Bladder
Gallbladder
T5 Vertebral Body
L4 Vertebral Body
Proximal Humerus
Sacrum
C6 Vertebral Body
Body of Ilium
Proximal Femur
Sternum
Intestine
Wing of Ilium
Renal Cortex
Superficial Cervical LN
Popliteal LN
Mid Femur
Liver
Mid Humerus
Spleen
Distal Humerus
Myocardium
Epaxial Muscle
Distal Femur
Brain
Lung

SUVmean

SUVmax

mean (SD)

mean (SD)

59.65
13.00
7.08
7.92
5.73
6.80
6.55
6.42
4.44
4.07

(30.79)
(3.75)
(2.16)
(2.03)
(2.18)
(1.24)
(1.12)
(1.33)
(1.53)
(0.90)
—
3.27 (1.47)
2.30 (0.41)
1.31 (1.03)
1.28 (0.60)
1.37 (0.38)
1.60 (0.36)
1.43 (0.42)
1.07 (0.32)
1.11 (0.24)
1.01 (0.24)
1.03 (0.27)
0.30 (0.18)
0.29 (0.08)
0.28 (0.09)

100.17
29.79
11.10
10.88
10.66
10.22
9.67
9.33
7.20
6.03
5.30
5.03
4.83
1.93
1.80
1.80
1.78
1.75
1.37
1.31
1.20
1.13
0.57
0.41
0.36

(49.75)
(11.34)
(3.44)
(3.08)
(2.75)
(2.01)
(1.76)
(1.99)
(2.55)
(1.74)
(0.84)
(2.15)
(1.59)
(1.70)
(0.88)
(0.58)
(0.42)
(0.56)
(0.43)
(0.28)
(0.32)
(0.28)
(0.28)
(0.11)
(0.13)

SUV, standardized uptake value; SD, standard deviation.
SUVs for all paired structure regions of interest were calculated by summing data for both left
and right sides. Measurements were made 77.10 ± 12.83 (mean±SD) minutes after injection. All
SUVs were decay corrected to injection time.
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Figure 2.1 Fused positron emission tomography/computed tomography (PET/CT)
images depicting selected regions of interest (ROI) used to measure biodistribution in
dogs. (A) ROIs outlining the left (purple) and right (teal) renal cortices were drawn to
exclude the renal pelvises (asterisks) on dorsal plane images. The splenic ROI is
outlined in blue. (B) ROI outlining the right proximal aspect of the humerus drawn to
approximate clinical sampling site (red). (C) Transverse plane images were used to
outline the 5th thoracic vertebral body (pink). (D) Large dorsal plane ROI outlining a
representative portion of the small intestine (green).
Sp = spleen, black arrowhead = tracer uptake within gallbladder
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Figure 2.2 Representative images illustrating 18FLT whole-body biodistribution patterns
observed in healthy adult dogs at 77.10 ± 12.83 minutes (mean±SD) minutes postinjection. Dorsal (A) and sagittal (B) plane positron emission tomography maximum
intensity projections are provided. Each dorsal plane image corresponds to the sagittal
plane image directly below. Image display settings are the same throughout the series.
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Figure 2.3 Focal site of presumed splenic extramedullary hematopoiesis in one dog.
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PART 3
RELATIVE SKELETAL DISTRIBUTION OF PROLIFERATING MARROW IN THE
ADULT DOG DETERMINED USING

18

FLT-PET/CT IMAGING
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This part is yet to be submitted for publication by Rowe JA, Osborne D, Wall JS, Akula
M, Kennel SJ, Galyon GD, Stuckey AC, Reed RB, and Leblanc AK.
My primary contributions to this paper include (1) developing the project, (2) image and
data analysis, (3) creation of figures and tables, (4) all of the writing
Abstract
3’-deoxy-3’-[18F]fluorothymidine (18FLT) is a radiopharmaceutical tracer used with
positron emission tomography (PET), often in combination with computed tomography
(CT), to image DNA synthesis, and thus, cellular proliferation. Characteristic
accumulation of the tracer within hematopoietic bone marrow provides a noninvasive
means to assess marrow activity and distribution throughout the living animal. The
present study utilizes three-dimensional analysis of

18

FLT-PET/CT scans to quantify the

relative skeletal distribution of active marrow by anatomic site in the dog. Scans were
performed on six healthy, adult (3 to 6 years of age), mixed-breed dogs using a
commercially available PET/CT scanner consisting of a 64-slice helical CT scanner
combined with an integrated whole-body, high-resolution LSO PET scanner. Regions of
interest (ROIs) encompassing 11 separate skeletal regions (skull, cervical spine,
thoracic spine, lumbar spine, sacrum, ribs, sternum, scapulae, proximal humeri, ossa
coxarum, and proximal femora) were manually drawn based on CT images and
thresholded by standardized uptake value to delineate bone marrow activity. Activity
within each skeletal region was then divided by the total skeletal activity to derive the
percent of overall active marrow within an individual site. The majority of active marrow
was located within the vertebral column. Of the sites traditionally accessed clinically for
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marrow sampling, the proximal humerus contained the largest percentage, followed by
the ossa coxarum, proximal femur, and sternum, respectively. This information may be
used to guide selection of traditional marrow sampling sites as well as inform efforts to
spare important sites of hematopoiesis in radiation therapy planning.
Introduction
Bone marrow is a dynamic organ found throughout the skeleton within the medullary
cavities of long bones and the interstices of spongy bone. In the neonate, most of the
marrow is active and functions in the formation of blood cells, known as red or
hematopoietic marrow. As an animal ages, however, much of the marrow is
progressively replaced by fat, particularly in the extremities [1]. As a result, active
marrow is normally restricted to portions of the axial and proximal appendicular skeleton
of the adult. Since much of the axial hematopoietic marrow is difficult to access
clinically, most diagnostic sampling in veterinary medicine is limited to a few accessible
sites within the appendicular portion of the distribution.
Compared to most tissues, hematopoietic marrow is particularly sensitive to radiation
toxicity. Doses as low as 2-4 Gy have been shown to be capable of producing
reductions of both cellularity [2] and proliferation [3]. Fractionated doses beyond 30Gy
generally produce permanent ablation [4], but a local fractionated dose of only 18Gy
was sufficient to produce longstanding cell death in the adjacent vertebral marrow of a
dog receiving intensity-modulated radiation therapy (IMRT) for a primary lung tumor (the
lung mass itself received a fractionated total dose of 30Gy as a palliative therapy
protocol) [5]. Although the ultimate clinical impact of bone marrow suppression also
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depends on volume, the concurrent use of chemotherapy and/or the potential to expose
rather large areas of bone marrow to lower radiation doses with techniques like IMRT
make detailed knowledge of marrow distribution an important consideration in
radiotherapy planning [6].
To date, there are few reports that provide specific information about the overall skeletal
distribution of canine hematopoietic marrow, and most available data are several
decades old. Existing canine functional marrow distribution data have been based on
the uptake of

59

Fe and 99mTc-sulfur colloid by erythroid precursors and

reticuloendothelial cells, respectively [7]. Additionally, local cellularity estimates have
been provided based on microscopic examinations of samples collected from several
sites throughout the skeleton of euthanized animals [8]. Unfortunately, both studies
appear to be based on relatively young animals; as a result, it is not clear whether their
results accurately reflect marrow distribution in the mature dog.
Today, positron emission tomography combined with computed tomography (PET/CT)
offers a state-of-the-art method to image and quantify whole-body bone marrow activity.
Compared to other modern techniques like magnetic resonance imaging (MRI), which
provides an anatomical approach to imaging marrow distribution based largely on its
relative fat and water content [9], PET/CT more directly interrogates marrow function by
exploiting specific physiologic pathways that mediate the distribution of certain positronemitting radiopharmaceuticals. In particular, PET/CT using 3'-deoxy-3'[18F]fluorothymidine (18FLT) has gained attention in recent years as a powerful tool to
analyze marrow proliferation [5, 6, 10-15]. As a substrate for the pyrimidine salvage
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pathway of DNA synthesis,

18

FLT enters proliferating cells and becomes trapped due to

phosphorylation by thymidine kinase 1 (TK1) [16-18]. Although it is not subsequently
incorporated into DNA, TK1 expression is tightly regulated to the synthetic phase of the
cell cycle, and

18

FLT retention in various tumors has generally correlated well with

traditional assessments of cellular proliferation [18-24]. Since the salvage pathway is
particularly robust in hematopoietic marrow due to the recovery of DNA liberated by red
blood cell enucleation [25], 18FLT-PET/CT is especially well-suited for assessing the
distribution of proliferating marrow.
Using existing whole-body 18FLT-PET/CT scans from normal dogs, the present study
seeks to analyze uptake within the marrow compartment to quantify the relative
distribution of active marrow throughout the skeleton by anatomical site. This
information will provide updated distribution data for the adult dog, and may be used to
improve bone marrow sparing efforts during radiotherapy planning or to inform clinical
selection of sampling sites for aspirates and biopsies.
Methods
18

FLT-PET/CT scans from six adult, University of Tennessee-maintained, research dogs

were utilized to gather data on proliferative bone marrow distribution. The dogs that
were imaged ranged in age from 3 to 6 years (mean = 4.67 years), weighed between
15.45 kg and 25.91 kg (mean = 19.09 kg), and included one intact male, one castrated
male, and four spayed females. Routine history records as well as results of physical
examination, hematology, clinical chemistry panels, and whole-body CT imaging were
evaluated to verify that the animals had no underlying adverse health conditions.
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Scans were performed in ventral recumbency under general anesthesia 77.10 ± 12.83
minutes (mean±SD) following intravenous injection of either 146.34 ± 0.26 MBq

18

FLT

(mean ± SD; 2 animals) or 66.88 ± 9.98 MBq 18FLT (mean±SD; 4 animals). The 18FLT
injected was produced on-site by the radiochemistry laboratory of the Molecular Imaging
and Translational Research Program at the University of Tennessee Graduate School
of Medicine and was verified by HPLC to be >99% radiochemically pure. The scans
were produced on a Biograph mCT (Siemens Medical Solutions USA, Inc., Knoxville,
TN) which combines a 64-slice helical CT scanner with a high resolution LSO PET
scanner within a single housing. CT and PET imaging were performed in sequence with
no alteration in subject positioning. CT scans were performed at 120 kV and 150 mAs
with Care Dose™ using a 0.8 pitch and 0.6 mm acquisition slice width but were
reconstructed using 2.5 mm slice thicknesses for image analysis. PET imaging was
performed over 9-11 bed positions in order to encompass the entire body of the dogs
and immediately followed completion of the CT scan. Each bed position was imaged
over 3 minutes with an energy acceptance window of 435-650 keV. PET reconstruction
utilized CT data for attenuation correction and was performed using the TrueX algorithm
(Siemens Medical Solutions USA, Inc., Knoxville, TN) with 3 iterations and 12 subsets
resulting in a reconstructed pixel size of 4.07 mm x 4.07 mm. Data was normalized and
corrected for dead time, scatter, and radioactive decay.
Regions of interest (ROIs) encompassing 11 separate skeletal sites (skull, cervical
spine, thoracic spine, lumbar spine, sacrum, ribs, sternum, scapulae, proximal humeri,
ossa coxarum, and proximal femora) were defined by a veterinarian trained in molecular
imaging analysis using dedicated analysis software (Inveon Research Workplace v3.0,
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Siemens Medical Solutions USA, Inc., Knoxville, TN). For each skeletal region, a 3dimensional ROI was initially drawn using CT image data with care taken to precisely
follow anatomical boundaries in all image planes. Once the ROI was confirmed to
encompass the entire skeletal region and exclude neighboring skeletal sites, coregistered PET data were utilized to tailor the ROI based on standardized uptake value
(SUV). A minimum SUV threshold of 2.0 was employed to limit the ROI to bone marrow
activity and exclude counts from surrounding tissues (a representative image of
thresholded vertebral ROIs is depicted in Figure 3.1). Tracer activity was measured
within each thresholded ROI and divided by total skeletal activity to derive the percent of
active marrow within each skeletal site.
Results
The relative percentage of proliferative bone marrow by anatomical region is organized
in Table 3.1 and illustrated in Figure 3.2. The measured mean ± standard deviation
percentage of active marrow by skeletal site was 5.74 ± 1.08 for the scapulae, 10.10 ±
3.81 for the humeri, 3.98 ± 1.80 for the femora, 6.76 ± 1.03 for the ossa coxarum, 4.08 ±
0.68 for the sacrum, 19.65 ± 2.27 for the lumbar spine, 32.08 ± 3.72 for the thoracic
spine, 9.59 ± 2.11 for the cervical spine, 0.22 ± 0.19 for the skull, 2.67 ± 1.00 for the
sternum, and 5.14 ± 2.10 for the ribs. Percentages listed for bilateral structures are
summed.
Appendicular proliferative marrow did not extend beyond the proximal aspects of the
humeri or femora in any of the scans included in this study. Marrow activity within the
skull was minimal and concentrated caudally. Vertebral activity, which represented the
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majority of active marrow measured, was predominately within vertebral bodies;
however, some activity extended into several larger vertebral processes. A 3dimensional image of skeletal marrow activity is depicted in Figure 3.3.
Discussion
The relative skeletal distribution of proliferating marrow determined by 18FLT-PET/CT
reflects what would be expected in an adult animal, with the bulk of marrow activity
concentrated along the axis of the trunk and adjacent limb bones. When compared with
the previous description by Greenberg et al [7], several similarities are observed.
Notably, the relative distribution based on

18

FLT uptake was within approximately 2

percent of the previous estimates determined by both

59

Fe and 99mTC-sulfur colloid for

the scapulae, humeri, sacrum, skull, and sternum. Further, all three methods indicate
that around 10 percent of total skeletal marrow activity lies within the proximal aspect of
the humerus, one of the most commonly and easily accessible marrow sampling sites in
veterinary species. Relative distribution was somewhat lower in other common sampling
sites, such as the iliac crest and proximal femur, suggesting that sampling from the
proximal humerus might be preferable in the dog. Larger differences were observed for
other sites, with distribution comparatively biased toward the vertebral column and away
from the ossa coxarum, femora, and ribs of the animals included in the present study.
The disparity was most conspicuous in the measurements of the ribs and thoracic
spine, where estimates using 18FLT were approximately 15 percent lower or higher,
respectively.
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Despite a paucity of information about marrow conversion age with respect to specific
skeletal sites in the dog, MRI studies suggest that conversion in the distal femur likely
occurs between 1 and 3 years of age [26-29]. Although age was not reported in the
Greenberg study [7], marrow activity was described in the distal femora and proximal
tibiae. It is therefore probable that the animals used were somewhat younger than those
described herein and may have still been undergoing marrow conversion. All of the
dogs imaged by 18FLT were greater than 3 years of age and none displayed similar
uptake near the stifle. While this likely explains the differences in femoral
measurements, it is unclear the extent to which age-related conversion explains the
discrepancies between the measurements of the ribs or the ossa coxarum, a tissue that
generally maintains the presence of red marrow despite advanced age [26, 30]. Further
studies imaging dogs of progressive ages are needed to define the pattern and timing of
marrow conversion in the canine.
Although comparisons between species should be considered with caution, it is
interesting to compare the present canine percentages with those determined in
humans using similar technology. A 2011 study by Hayman et al [6] used

18

FLT-PET/CT

scans from 13 human cancer patients to describe relative skeletal distribution of
hematopoietic marrow in much the same way as presented herein. While general trends
were similar between our measurements of the dog and those of the human, only the
mean values for the femoral, scapular, and sternal anatomical sites were within 2
percent of one another. Our results indicate that the dog has a greater percentage of
active marrow within the humerus and cervical, thoracic, and lumbar portions of the
vertebral column, but a relatively smaller percentage within the skull, sacrum, ribs, and
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ossa coxarum. The ribs and clavicles were grouped in the human data, likely explaining
some of the difference observed since the canine clavicle is extremely small and was
therefore not included in our assessments. Interestingly, the difference measured
between the ossa coxarum of the two species was rather large at approximately 18.5
percent (6.76 versus 25.3 percent). It is probable that differences in the anatomical
proportions of the various sites explains much of the variation between the two species.
This data has several potential limitations. First, the small sample size consisted of only
six scans, all of which were from mixed breed dogs of moderate age. Consequently,
analysis was limited to basic descriptive statistics and the ability to examine potential
factors which may influence bone marrow distribution, such as sex, breed, or life stage,
was limited. ROIs were drawn to exclude adjacent soft tissues and neighboring skeletal
sites. As a result, partial volume effects (PVE) may influence activity measurements
between adjoining sites or within very small ROIs due to spillover of imaged activity and
averaging within voxels. PVE typically occur whenever an object is less than three times
the full width at half maximum (FWHM) of the reconstructed image resolution [31].
Influence is likely minimal for most skeletal regions described, but evaluations of relative
distribution in narrow or small regions of uptake, like the ribs or skull, may be
underestimated due to this effect.
Despite potential limitations,

18

FLT-PET/CT provides a robust, whole-body assessment

of proliferative activity within the marrow compartment. The relative distribution data
reported herein provides a modern estimate of marrow activity by skeletal site for the
adult dog based on cellular proliferation. This information should assist planning, both
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by radiation oncologists aiming to avoid important sites of proliferative marrow and by
clinicians choosing sites that are most likely to yield high quality samples for diagnostic
testing.
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Table 3.1 Percentage of canine total bone marrow activity by skeletal site

Dog 1

Dog 2

Dog 3

Dog 4

Dog 5

Dog 6

Scapulae

7.2

4.6

4.6

6.4

5.2

6.4

5.7 ± 1.1

Proximal Humerus

5.5

6.4

12.5

12.2

8.8

15.2

10.1 ± 3.8

Proximal Femur

1.6

3.2

4.2

5.1

3.1

6.8

4.0 ± 1.8

Ossa Coxarum

6.6

6.7

7.4

7.5

4.8

7.4

6.8 ± 1.0

Sacrum

3.5

4.4

5.2

4.2

3.5

3.6

4.1 ± 0.7

Lumbar Spine

21.1

21.4

16.4

19.0

22.2

17.8

19.7 ± 2.3

Thoracic Spine

33.2

37.5

26.9

31.8

33.9

29.2

32.1 ± 3.7

Cervical Spine

11.6

10.5

10.0

5.8

11.0

8.7

9.6 ± 2.1

Skull

0.2

0.1

0.6

0.0

0.2

0.2

0.2 ± 0.2

Sternum

4.2

2.0

3.6

1.7

2.5

2.0

2.7 ± 1.0

Ribs

5.4

3.3

8.5

6.3

4.7

2.7

5.1 ± 2.1

Site

Mean

±

SD

SD = Standard Deviation
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Figure 3.1 Sagittal plane image depicting canine vertebral column regions of interest.
Cervical (yellow), thoracic (teal), lumbar (pink), and sacral (green) regions are shown.
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Figure 3.2 Box plots showing percentage distribution of proliferative bone marrow by
skeletal site in the adult dog (n = 6).
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Figure 3.3 Three-dimensionally reconstructed image of canine skeletal marrow activity.
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CONCLUSION

106

The work presented herein documents the normal physiologic distribution of 3’-deoxy3’-[18F]fluorothymidine (18FLT) in adult dogs and cats. The quantitative measurements
included throughout this dissertation may serve as reference values to guide image
interpretation in future clinical studies using this tracer to evaluate animals with
suspected disease. Observation of similar tracer distribution characteristics in cats, as
compared to dogs and humans, validates the first documented use of

18

FLT in this

species. Although additional studies are needed to define the metabolism of

18

FLT in

cats and further define that of dogs, positron emission tomography/computed
tomography (PET/CT) utilizing 18FLT represents a robust diagnostic tool for noninvasive
imaging of proliferative tissues in veterinary patients. As such, the details of normal
canine and feline biodistribution will become increasingly relevant as veterinary access
to PET and PET/CT continues to grow.
The use of

18

FLT-PET/CT to characterize marrow activity has been well defined in

human medicine, but this technology has not been used previously for this purpose in
veterinary species. Existing descriptions of canine marrow distribution appear to have
been based on younger animals that were likely still undergoing marrow conversion. As
a result, the present use of

18

FLT-PET/CT to evaluate the relative skeletal distribution of

proliferating marrow in dogs may represent the only comprehensive whole-body
description of the adult pattern of hematopoietic marrow distribution in this species,
information that is valuable when selecting diagnostic sampling sites or during
radiotherapy planning to minimize hematologic toxicity. Further studies utilizing this
technology to define the age-related progression of marrow conversion throughout the
skeleton are warranted as such information is limited for veterinary species.
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